# A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

> **NCT03933202** · — · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 291 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Cladribine Tablets

## Key facts

- **NCT ID:** NCT03933202
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-22
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933202, "A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03933202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*